AAPL329.40-9.00 (-2.66%) ▼|ABBV263.29-2.99 (-1.12%) ▼|ABT100.95-0.03 (-0.03%) ▼|ACN177.12+2.65 (+1.52%) ▲|ADBE233.17+2.16 (+0.94%) ▲|AMAT512.01+25.25 (+5.19%) ▲|AMD607.57-0.30 (-0.05%) ▼|AMGN423.64+5.51 (+1.32%) ▲|AMT167.35-0.65 (-0.39%) ▼|AMZN246.67+0.52 (+0.21%) ▲|AVGO355.10+5.53 (+1.58%) ▲|AXP305.40-0.93 (-0.30%) ▼|BA187.68+3.29 (+1.78%) ▲|BAC54.96-0.51 (-0.92%) ▼|BKNG162.34-1.53 (-0.93%) ▼|BLK1,067.94-3.31 (-0.31%) ▼|BMY62.86-1.02 (-1.60%) ▼|BNY146.98-1.46 (-0.98%) ▼|BRK-B502.35-0.74 (-0.15%) ▼|C130.80-0.51 (-0.39%) ▼|CAT826.64+6.69 (+0.82%) ▲|CL86.46-0.06 (-0.07%) ▼|CMCSA21.60-0.19 (-0.87%) ▼|COF196.46+0.00 (+0.00%) ▲|COP125.44-0.60 (-0.48%) ▼|COST924.59+1.67 (+0.18%) ▲|CRM225.31-1.96 (-0.86%) ▼|CSCO106.94+0.20 (+0.19%) ▲|CVS87.10-0.75 (-0.85%) ▼|CVX204.38-1.99 (-0.96%) ▼|DE680.50-9.09 (-1.32%) ▼|DHR226.11-1.22 (-0.54%) ▼|DIS105.41-0.18 (-0.17%) ▼|DUK114.21+0.80 (+0.71%) ▲|EMR157.24-2.15 (-1.35%) ▼|FDX287.47-2.18 (-0.75%) ▼|GD332.34-1.82 (-0.54%) ▼|GE317.89-0.35 (-0.11%) ▼|GEV962.49+12.72 (+1.34%) ▲|GILD151.28-0.93 (-0.61%) ▼|GM80.47-0.17 (-0.21%) ▼|GOOG337.32-1.84 (-0.54%) ▼|GOOGL340.92-1.83 (-0.53%) ▼|GS916.24-0.04 (0.00%) ▼|HD288.04-1.85 (-0.64%) ▼|HON210.13-1.39 (-0.66%) ▼|IBM219.99-0.68 (-0.31%) ▼|INTC115.93-0.10 (-0.09%) ▼|INTU268.03-1.37 (-0.51%) ▼|ISRG412.18-2.61 (-0.63%) ▼|JNJ267.57-4.38 (-1.61%) ▼|JPM334.98-1.61 (-0.48%) ▼|KO86.84-0.34 (-0.39%) ▼|LIN473.37+1.33 (+0.28%) ▲|LLY1,184.63-0.15 (-0.01%) ▼|LMT512.21-5.89 (-1.14%) ▼|LOW187.26-0.40 (-0.21%) ▼|LRCX323.86+9.39 (+2.99%) ▲|MA563.58-4.68 (-0.82%) ▼|MCD233.98+0.38 (+0.16%) ▲|MDLZ59.32-0.86 (-1.43%) ▼|MDT87.09-2.41 (-2.69%) ▼|META738.79+23.17 (+3.24%) ▲|MMM168.49-0.99 (-0.58%) ▼|MO68.72-0.41 (-0.59%) ▼|MRK149.28+0.59 (+0.40%) ▲|MS192.76-0.88 (-0.45%) ▼|MSFT508.96-0.26 (-0.05%) ▼|MU1,065.08+11.10 (+1.05%) ▲|NEE75.89+0.40 (+0.53%) ▲|NFLX70.30+1.07 (+1.55%) ▲|NKE35.84-0.55 (-1.51%) ▼|NOW129.94-1.51 (-1.15%) ▼|NVDA227.21-1.65 (-0.72%) ▼|ORCL137.79+5.19 (+3.91%) ▲|PEP128.69+0.19 (+0.15%) ▲|PFE28.72+0.00 (+0.00%) ▲|PG148.32-0.71 (-0.48%) ▼|PLTR186.97-0.51 (-0.27%) ▼|PM193.90+0.14 (+0.07%) ▲|QCOM184.10-3.38 (-1.80%) ▼|RTX186.94-0.72 (-0.38%) ▼|SBUX95.43+0.16 (+0.17%) ▲|SCHW99.10+0.80 (+0.81%) ▲|SO83.45+1.10 (+1.34%) ▲|SPG204.28-0.25 (-0.12%) ▼|T24.48-0.42 (-1.69%) ▼|TMO679.61+1.01 (+0.15%) ▲|TMUS162.98-3.47 (-2.08%) ▼|TSLA352.84-4.61 (-1.29%) ▼|TXN281.69+3.38 (+1.21%) ▲|UBER69.36+1.20 (+1.76%) ▲|UNH374.94-2.89 (-0.76%) ▼|UNP274.15+0.05 (+0.02%) ▲|UPS93.93-0.32 (-0.34%) ▼|USB58.14-0.64 (-1.09%) ▼|V365.88-1.86 (-0.51%) ▼|VZ45.98-0.70 (-1.50%) ▼|WFC80.48-0.33 (-0.41%) ▼|WMT106.80-1.93 (-1.78%) ▼|XOM161.35-1.17 (-0.72%) ▼|AAPL329.40-9.00 (-2.66%) ▼|ABBV263.29-2.99 (-1.12%) ▼|ABT100.95-0.03 (-0.03%) ▼|ACN177.12+2.65 (+1.52%) ▲|ADBE233.17+2.16 (+0.94%) ▲|AMAT512.01+25.25 (+5.19%) ▲|AMD607.57-0.30 (-0.05%) ▼|AMGN423.64+5.51 (+1.32%) ▲|AMT167.35-0.65 (-0.39%) ▼|AMZN246.67+0.52 (+0.21%) ▲|AVGO355.10+5.53 (+1.58%) ▲|AXP305.40-0.93 (-0.30%) ▼|BA187.68+3.29 (+1.78%) ▲|BAC54.96-0.51 (-0.92%) ▼|BKNG162.34-1.53 (-0.93%) ▼|BLK1,067.94-3.31 (-0.31%) ▼|BMY62.86-1.02 (-1.60%) ▼|BNY146.98-1.46 (-0.98%) ▼|BRK-B502.35-0.74 (-0.15%) ▼|C130.80-0.51 (-0.39%) ▼|CAT826.64+6.69 (+0.82%) ▲|CL86.46-0.06 (-0.07%) ▼|CMCSA21.60-0.19 (-0.87%) ▼|COF196.46+0.00 (+0.00%) ▲|COP125.44-0.60 (-0.48%) ▼|COST924.59+1.67 (+0.18%) ▲|CRM225.31-1.96 (-0.86%) ▼|CSCO106.94+0.20 (+0.19%) ▲|CVS87.10-0.75 (-0.85%) ▼|CVX204.38-1.99 (-0.96%) ▼|DE680.50-9.09 (-1.32%) ▼|DHR226.11-1.22 (-0.54%) ▼|DIS105.41-0.18 (-0.17%) ▼|DUK114.21+0.80 (+0.71%) ▲|EMR157.24-2.15 (-1.35%) ▼|FDX287.47-2.18 (-0.75%) ▼|GD332.34-1.82 (-0.54%) ▼|GE317.89-0.35 (-0.11%) ▼|GEV962.49+12.72 (+1.34%) ▲|GILD151.28-0.93 (-0.61%) ▼|GM80.47-0.17 (-0.21%) ▼|GOOG337.32-1.84 (-0.54%) ▼|GOOGL340.92-1.83 (-0.53%) ▼|GS916.24-0.04 (0.00%) ▼|HD288.04-1.85 (-0.64%) ▼|HON210.13-1.39 (-0.66%) ▼|IBM219.99-0.68 (-0.31%) ▼|INTC115.93-0.10 (-0.09%) ▼|INTU268.03-1.37 (-0.51%) ▼|ISRG412.18-2.61 (-0.63%) ▼|JNJ267.57-4.38 (-1.61%) ▼|JPM334.98-1.61 (-0.48%) ▼|KO86.84-0.34 (-0.39%) ▼|LIN473.37+1.33 (+0.28%) ▲|LLY1,184.63-0.15 (-0.01%) ▼|LMT512.21-5.89 (-1.14%) ▼|LOW187.26-0.40 (-0.21%) ▼|LRCX323.86+9.39 (+2.99%) ▲|MA563.58-4.68 (-0.82%) ▼|MCD233.98+0.38 (+0.16%) ▲|MDLZ59.32-0.86 (-1.43%) ▼|MDT87.09-2.41 (-2.69%) ▼|META738.79+23.17 (+3.24%) ▲|MMM168.49-0.99 (-0.58%) ▼|MO68.72-0.41 (-0.59%) ▼|MRK149.28+0.59 (+0.40%) ▲|MS192.76-0.88 (-0.45%) ▼|MSFT508.96-0.26 (-0.05%) ▼|MU1,065.08+11.10 (+1.05%) ▲|NEE75.89+0.40 (+0.53%) ▲|NFLX70.30+1.07 (+1.55%) ▲|NKE35.84-0.55 (-1.51%) ▼|NOW129.94-1.51 (-1.15%) ▼|NVDA227.21-1.65 (-0.72%) ▼|ORCL137.79+5.19 (+3.91%) ▲|PEP128.69+0.19 (+0.15%) ▲|PFE28.72+0.00 (+0.00%) ▲|PG148.32-0.71 (-0.48%) ▼|PLTR186.97-0.51 (-0.27%) ▼|PM193.90+0.14 (+0.07%) ▲|QCOM184.10-3.38 (-1.80%) ▼|RTX186.94-0.72 (-0.38%) ▼|SBUX95.43+0.16 (+0.17%) ▲|SCHW99.10+0.80 (+0.81%) ▲|SO83.45+1.10 (+1.34%) ▲|SPG204.28-0.25 (-0.12%) ▼|T24.48-0.42 (-1.69%) ▼|TMO679.61+1.01 (+0.15%) ▲|TMUS162.98-3.47 (-2.08%) ▼|TSLA352.84-4.61 (-1.29%) ▼|TXN281.69+3.38 (+1.21%) ▲|UBER69.36+1.20 (+1.76%) ▲|UNH374.94-2.89 (-0.76%) ▼|UNP274.15+0.05 (+0.02%) ▲|UPS93.93-0.32 (-0.34%) ▼|USB58.14-0.64 (-1.09%) ▼|V365.88-1.86 (-0.51%) ▼|VZ45.98-0.70 (-1.50%) ▼|WFC80.48-0.33 (-0.41%) ▼|WMT106.80-1.93 (-1.78%) ▼|XOM161.35-1.17 (-0.72%) ▼|
18.7 C
New York
Wednesday, September 30, 2026

Tag: releases

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

Shokz Support 5 Pro Athletes Competing In The 2025 Western States Endurance Run

AUSTIN, Texas, June 21, 2025 /PRNewswire/ -- Shokz, a pioneer in open-ear audio technology, announces 5 Pro Athletes representing the brand will be competing...

IIM Udaipur Concludes Executive Education Training Program for PM SHRI School Principals in Collaboration with RSSP Jaipur

UDAIPUR, India, June 21, 2025 /PRNewswire/ -- Indian Institute of Management Udaipur (IIM Udaipur), in collaboration with the Rajasthan School Shiksha Parishad (RSSP), Jaipur,...

Dialogue on China-ASEAN Cultural Heritage Successfully Concludes in Tianshui

TIANSHUI, China, June 21, 2025 /PRNewswire/ -- To encourage exchange and cooperation in cultural heritage preservation, promote mutual learning among civilizations, and advance the...

William Stern’s Cardiff Redefines Working Capital for Small Businesses

Cardiff CEO William Stern is modernizing the merchant cash advances (MCA) concept, also known as Revenue Based Financing. SAN DIEGO, June 21, 2025 /PRNewswire/ -- Traditional...

MolecuLight Showcases Innovative Multimodal Imaging with Thermal Capabilities at St. Louis Wound & Vascular Symposium

PITTSBURGH, June 21, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, is proud to showcase its presence...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

TEAMSTERS NURSES AT COREWELL TO RALLY AGAINST EMPLOYERS’ ATTACKS

Nurses to Rally Outside Detroit Ahead of Contract Negotiations DETROIT, June 21, 2025 /PRNewswire/ -- Nurses at Corewell Health East, represented by Teamsters Local 2024, will...

SIFF 2025: The Premier Launchpad for Chinese Movies and Their Global Promotion

SHANGHAI, June 21, 2025 /PRNewswire/ -- The 27th Shanghai International Film Festival (SIFF) is currently in full swing, vividly demonstrating the booming momentum of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsReleases